Is Asarfi Hospital overvalued or undervalued?

As of 14 November 2025, Asarfi Hospital's valuation grade has moved from very attractive to attractive, indicating a shift in its perceived value. The company is currently assessed as fairly valued. Key ratios include a PE Ratio of 31.38, an EV to EBITDA of 16.34, and a ROE of 12.97%.
In comparison to its peers, Asarfi Hospital's PE Ratio is significantly lower than that of Apollo Hospitals, which stands at 63.77, and Max Healthcare, which is at 89.07, both of which are categorized as very expensive. The company's recent stock performance has outpaced the Sensex, with a year-to-date return of 75.1% compared to the Sensex's 8.22%, reinforcing the attractiveness of its current valuation.